AbbVie Management
Management criteria checks 2/4
AbbVie's CEO is Rick Gonzalez, appointed in Jan 2013, has a tenure of 11.25 years. total yearly compensation is $25.66M, comprised of 6.6% salary and 93.4% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth $93.00M. The average tenure of the management team and the board of directors is 1.4 years and 11.3 years respectively.
Key information
Rick Gonzalez
Chief executive officer
US$25.7m
Total compensation
| CEO salary percentage | 6.6% |
| CEO tenure | 11.3yrs |
| CEO ownership | 0.03% |
| Management average tenure | 1.4yrs |
| Board average tenure | 11.3yrs |
Recent management updates
Recent updates
AbbVie: Great To Be Proven Wrong - Still Not A Buy
Apr 14AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision
Apr 08AbbVie: Strong Cash Flow Growth Fuels Dividend Growth
Mar 08AbbVie: Things Are Getting Clearer
Feb 05AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade)
Jan 30AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.55
Jan 05
AbbVie: Time To Lock In Gains (Rating Downgrade)
Jan 03AbbVie Vs. GSK: Dual Dominance In Pharma
Dec 23AbbVie's (NYSE:ABBV) Upcoming Dividend Will Be Larger Than Last Year's
Dec 124.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024
Nov 29AbbVie (NYSE:ABBV) Has Announced That It Will Be Increasing Its Dividend To $1.55
Nov 28AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks
Nov 21AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.55
Oct 30AbbVie Stock Still A Hold Despite Positive Third Quarter 2023 Results
Oct 30AbbVie Q3 Earnings Preview: Tough Comparison For Humira Shouldn't Derail Growth Plans
Oct 23AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014
Oct 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$26m | US$2m | US$5b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$9b |
| Mar 31 2023 | n/a | n/a | US$8b |
| Dec 31 2022 | US$26m | US$2m | US$12b |
| Sep 30 2022 | n/a | n/a | US$13b |
| Jun 30 2022 | n/a | n/a | US$13b |
| Mar 31 2022 | n/a | n/a | US$12b |
| Dec 31 2021 | US$24m | US$2m | US$11b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$7b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$24m | US$2m | US$5b |
| Sep 30 2020 | n/a | n/a | US$7b |
| Jun 30 2020 | n/a | n/a | US$7b |
| Mar 31 2020 | n/a | n/a | US$8b |
| Dec 31 2019 | US$22m | US$2m | US$8b |
| Sep 30 2019 | n/a | n/a | US$3b |
| Jun 30 2019 | n/a | n/a | US$4b |
| Mar 31 2019 | n/a | n/a | US$5b |
| Dec 31 2018 | US$21m | US$2m | US$6b |
| Sep 30 2018 | n/a | n/a | US$8b |
| Jun 30 2018 | n/a | n/a | US$6b |
| Mar 31 2018 | n/a | n/a | US$6b |
| Dec 31 2017 | US$23m | US$2m | US$5b |
Compensation vs Market: Rick's total compensation ($USD25.66M) is above average for companies of similar size in the US market ($USD13.51M).
Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.
CEO
Rick Gonzalez (69 yo)
11.3yrs
Tenure
US$25,661,972
Compensation
Mr. Richard A. Gonzalez, also known as Rick, serves as Chairman of AbbVie Inc. and has been its Chief Executive Officer at AbbVie Inc. since 2013. Mr. Gonzalez served as an Executive Vice President of Phar...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 11.3yrs | US$25.66m | 0.031% $ 93.0m | |
| President & COO | 1.8yrs | US$14.44m | 0.0056% $ 16.7m | |
| Executive VP & CFO | 1.8yrs | US$10.19m | 0.00087% $ 2.6m | |
| Executive VP & COO | less than a year | US$9.30m | 0.013% $ 38.3m | |
| Executive VP & Chief Commercial Officer | no data | US$15.35m | 0.0035% $ 10.6m | |
| Senior VP & Chief Scientific Officer of Global Research | no data | no data | 0.0061% $ 18.2m | |
| Senior Vice President of Investor Relations | no data | no data | no data | |
| Executive VP | 1.5yrs | no data | 0% $ 0 | |
| Senior VP | less than a year | no data | no data | |
| Executive VP & Chief Human Resources Officer | no data | US$3.30m | 0.00078% $ 2.3m | |
| Senior VP of AbbVie & President of Oncology | less than a year | no data | no data | |
| Executive VP and Chief Business & Strategy Officer | 1.3yrs | no data | 0.0032% $ 9.5m |
1.4yrs
Average Tenure
55yo
Average Age
Experienced Management: ABBV's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 11.3yrs | US$25.66m | 0.031% $ 93.0m | |
| Independent Director | 11.3yrs | US$385.59k | 0.00065% $ 2.0m | |
| Independent Director | 3.9yrs | US$380.78k | 0.0071% $ 21.2m | |
| Lead Independent Director | 11.3yrs | US$418.94k | 0.0014% $ 4.2m | |
| Independent Director | 11.3yrs | US$394.98k | 0.00090% $ 2.7m | |
| Independent Director | 11.3yrs | US$377.48k | 0% $ 0 | |
| Independent Director | 11.3yrs | US$369.98k | 0.00011% $ 330.2k | |
| Independent Director | 6.9yrs | US$369.98k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$380.78k | 0% $ 0 | |
| Independent Director | 5.9yrs | US$359.98k | no data | |
| Independent Director | 11.3yrs | US$461.18k | 0.000010% $ 30.0k | |
| Independnet Director | less than a year | no data | no data |
11.3yrs
Average Tenure
69yo
Average Age
Experienced Board: ABBV's board of directors are seasoned and experienced ( 11.3 years average tenure).